Updated Jul 16, 2026 · Last SEC filing 2026-06-26
Definium Therapeutics, Inc. (DFTX) has filed 16 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-26. 7 Form 8-K material event filings were reported by DFTX in the last 90 days. 5 Form 144 notices of proposed sale were filed for DFTX stock. InsiderAlpha tracks every DFTX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001813814 |
|---|
| Form 4 filings (90d) | 16 |
|---|---|
| Form 8-K filings (90d) | 7 |
| Form 144 notices (90d) | 5 |
| Latest Form 4 filing | 2026-06-26 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer | S — Open-market sale | 13.0K | $45.03 | $586K | SEC | |
| Karlin Daniel | Chief Medical Officer | S — Open-market sale | 10.0K | $45.03 | $452K | SEC | |
| Roberts Brandi | Chief Financial Officer | S — Open-market sale | 3.0K | $45.03 | $136K | SEC | |
| Wiley Matthew T. | Chief Commercial Officer | S — Open-market sale | 2.9K | $45.03 | $129K | SEC | |
| Barrow Robert | Chief Executive Officer | S — Open-market sale | 29.2K | $45.03 | $1.32M | SEC | |
| Sullivan Mark | Chief Legal Officer | A — Grant or award | 62.5K | $0.00 | — | SEC | |
| Barrow Robert | Chief Executive Officer | A — Grant or award | 375.0K | $0.00 | — | SEC | |
| Roberts Brandi | Chief Financial Officer | A — Grant or award | 62.5K | $0.00 | — | SEC | |
| Wiley Matthew T. | Chief Commercial Officer | A — Grant or award | 62.5K | $0.00 | — | SEC | |
| Karlin Daniel | Chief Medical Officer | A — Grant or award | 100.0K | $0.00 | — | SEC | |
| Vallone Carol A | Insider | A — Grant or award | 4.7K | $0.00 | — | SEC | |
| Krebs Andreas | Insider | A — Grant or award | 4.7K | $0.00 | — | SEC | |
| CRYSTAL ROGER | Insider | A — Grant or award | 4.7K | $0.00 | — | SEC | |
| Adsett Roger | Insider | A — Grant or award | 3.6K | $0.00 | — | SEC | |
| Bruhn Suzanne Louise | Insider | A — Grant or award | 4.7K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Definium Therapeutics, Inc. (DFTX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Sullivan Mark | 2 | $586K |
| Bruhn Suzanne Louise | 2 | — |
| Karlin Daniel | 2 | $452K |
| Barrow Robert | 2 | $1.32M |
| Adsett Roger | 2 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in DFTX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live DFTX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.